- Home
- GXAI vs PPBT Comparison
GXAI vs PPBT Comparison
Compare GXAI & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GXAI | PPBT |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 45.3M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GXAI | PPBT |
|---|---|---|
| Price | $1.39 | $4.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 11.4M | 68.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,027.00 | N/A |
| Revenue This Year | $42,959.35 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1473.05 | N/A |
| 52 Week Low | $1.00 | $0.41 |
| 52 Week High | $2.96 | $5.18 |
Technical Indicators
Market Signals| Indicator | GXAI | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 51.20 | 67.45 |
| Support Level | $1.11 | $0.57 |
| Resistance Level | $1.39 | $5.18 |
| Average True Range (ATR) | 0.16 | 0.34 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 23.72 | 68.97 |
Price Performance
Historical ComparisonAbout GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.